Sanofi Press Release: AMETHIST Trial Discontinued
We regret to inform you that in Sanofi’s quarterly press release issued today that the…
2023 Cure GM1 Impact Report – Impact In 2023 And Beyond
Our summary of impact in 2023 is now available to read. After some time reflecting, everyone…
Cure GM1 to Collaborate with xCURES for Natural History Study Pilot
Cure GM1, a 501(c)(3) nonprofit organization located in Albany, CA, USA is proud to announce…
Over $461K Grant toward Enzyme Replacement Therapy with TEGA Therapeutics
TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR)…
Gelb Laboratory Publishes Third GM1 Newborn Screening Paper
Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood…
2022 Cure GM1 Impact Report – Impact in 2022 and Beyond
Our summary of impact in 2022 is now available to read. After some time reflecting,…
The Voice of the Patient Report from the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD)
You can now download and read the touching and impactful summary of input from GM1…
About the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with FDA
The GM1 Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) was held on Friday, October 14 as…
Cure GM1 Caregiver Preferences Study has been published
Our Caregiver Preferences study, The caregivers’ assessments of symptom impact and most important symptoms to…
Cure GM1 Foundation and TEGA Therapeutics Establish Collaboration to Develop GM1 Gangliosidosis Therapy
TEGA Cure GM1 Collaboration PDF TEGA WORLD Pres 2023